Abstract Library

#4119 Interim analysis of LANTana: Phase Ib study investigating up-regulation of somatostatin receptor-2 (SSTR2) with the de-methylating agent ASTX727 to allow [177Lu]Lu-DOTA-TATE in metastatic neuroendocrine tumors (NETs)

Introduction: To be suitable for [177Lu]Lu-DOTA-TATE, SSTR2 must be present on tumor surface as per positive uptake on [68Ga]Ga-DOTA-TATE-PET/CT. SSTR2 promoter methylation reduces SSTR2 expression; this can be reversed using a demethylating agent.

Conference:

Presenting Author:

Authors: Rzeniewicz K, Ward C, Khan S, Naik M, Qurashi M,

Keywords: neuroendocrine tumor, peptide receptor radionucleotide therapy, methylation, [68Ga]Ga-DOTA-peptide-PET, [177Lu]Lu-DOTA-TATE,

#3981 Identifying patients with undiagnosed small intestinal neuroendocrine tumors using statistical and machine learning: Model development and validation study

Introduction: Diagnosis of small intestinal neuroendocrine tumors (SI-NETs) is often delayed due to non-specific symptoms and lack of awareness among primary and secondary care physicians. Earlier diagnosis may lead to improved clinical and patient outcomes. Clinical prediction models using machine learning could present novel opportunities for expedited diagnosis in primary care.

Conference:

Presenting Author:

Authors: Clift A, Mahon H, Khan G, Boardman-Pretty F, Worker A,

Keywords: machine learning, artificial intelligence, diagnosis, neuroendocrine tumor,

#3727 PREF-NET: A patient preference and experience study of lanreotide autogel (LAN) administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in the UK

Introduction: The somatostatin analogue LAN is a common first-line treatment for NETs that can be given at home in a ready-to-use syringe every 4 weeks in the UK.

Conference:

Presenting Author: Khan M

Authors: Khan M, Davies L, Back M, Shah T, Pritchard D,

Keywords: patient participation, somatostatin analogues, injections, quality of life, value-based health care,

#3687 Lutetium-177 DOTATATE PRRT versus PRRT plus chemotherapy in metastatic well differentiated FDG-avid GEP-NETs – Results from a prospective cohort

Introduction: Combination therapy with PRRT and Capecitabine-Temozolomide (CAPE-TMZ) has benefited patients with FDG avid well-differentiated GEP-NETs.

Conference:

Presenting Author:

Authors: Puranik A, Rangarajan V, Shrikhande S, Ramaswamy A, Ostwal V,

Keywords: PRRT, capecitabine, temozolomide, FDG PET, DOTA PET,

#3642 GP-patient interactions and coding of neuroendocrine tumors (NETs) in primary care records

Introduction: Diagnostic delays in NETs are common with improved diagnosis times recently shown in Wales. Although studies have explored GP visits, these are based on patient surveys with recall bias and no exploration of GP coded data.

Conference:

Presenting Author: Olive S

Authors: Olive S, Gould H, Navaratnam J, Khan M,

Keywords: diagnosis, GP, primary care, coding,